Health Canada approved Eli Lilly and Company’s Kisunla (donanemab) for treating early symptomatic Alzheimer's disease.
The once-monthly treatment targets adults with mild cognitive impairment or mild dementia with confirmed amyloid pathology.
Canada represents the 48th market to authorize Kisunla globally.
This approval follows more than 35 years of research by Eli Lilly in the Alzheimer's field.
Patients may stop treatment once amyloid plaques are cleared from the brain.
The authorization supports Lilly’s strategic focus on advancing therapies for neurodegenerative diseases.